OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies, payers, providers and
patients, has engaged UHY LLP as its new auditor, effective
Monday, June 22. There were no accounting disagreements or issues
with the prior auditor.
UHY has 21 offices nationwide, with several local to the
company’s headquarters in Southeastern Michigan. It serves
companies ranging from mid-sized to the Fortune 500, throughout the
U.S. and around the globe.
“We are excited to welcome UHY as our new auditor,” said
OptimizeRx CFO, Doug Baker. “We anticipate using an auditor with
local offices to have a significant positive impact on the
efficiency of our audit, including the elimination of travel,
especially in the new COVID-19 world.”
For additional details, please see the company’s Form 8-K filed
Friday, June 26 and posted to the SEC Filings page on the company
website.
Baker added: “Just as an update, in our Form 10-K filed on March
26, we reported on two weaknesses in internal control. They had no
impact on our financial results and we received an unqualified
opinion on our financial statements for the year ended December 31,
2019. They are largely behind us, and we expect them to be
completely remediated and removed no later than the end of the
third quarter.”
OptimizeRx also reported that it has been listed again on the
Russell Microcap® and 3000® Indexes, following the conclusion of
the 2019 Russell indexes annual reconstitution, effective
today.
Membership in the Russell Microcap and 3000 Indexes, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE
Russell determines membership for its Russell indexes
primarily by objective market capitalization rankings and style
attributes. OptimizeRx has been listed on Russell Microcap and 3000
Indexes since 2019.
“Our renewed membership in the Russell Indexes represents
another important milestone for OptimizeRx, after generating record
Q1 results,” commented company CEO, William Febbo. “We believe this
listing reflects that we’ve arrived at an inflection point in terms
of growth and development with our acceleration in platform
adoption and the further transformation of the company’s revenue
model into SaaS-based enterprise-level deployments. We welcome this
greater visibility in the investment community as we continue to
expand our nationwide digital connectivity at the point-of-care and
our customer base, which now includes Epic and Cerner Health
Systems and the world’s top 20 pharmaceutical companies.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against the Russell U.S. indexes. Russell indexes
are part of FTSE Russell, a leading global index provider.
For more information about the Russell indexes reconstitution,
see the Russell Reconstitution section on the FTSE Russell
website.
About UHY LLPUHY LLP, certified public
accountants, and UHY Advisors, Inc. work together in an alternative
practice structure, to provide comprehensive audit, tax, advisory
and related services to clients in a wide range of industries. UHY
serves companies ranging from mid-sized to the Fortune 500,
throughout the United States and around the globe. It has offices
across the U.S. and, as a founder and independent member of UHY
International, has access to international resources in nearly 320
business centers and in excess of 98 countries. For more
information, go to uhy-us.com.
About FTSE RussellFTSE Russell is a leading
global index provider creating and managing a wide range of
indexes, data and analytic solutions to meet client needs across
asset classes, styles and strategies. Covering 98% of the
investable market, FTSE Russell indexes offer a true picture of
global markets, combined with the specialist knowledge gained from
developing local benchmarks around the world.
FTSE Russell index expertise and products are used
extensively by institutional and retail investors globally.
Approximately $16 trillion is currently benchmarked to FTSE Russell
indexes. For over 30 years, leading asset owners, asset managers,
ETF providers and investment banks have chosen FTSE Russell indexes
to benchmark their investment performance and create investment
funds, ETFs, structured products and index-based derivatives. FTSE
Russell indexes also provide clients with tools for asset
allocation, investment strategy analysis and risk management.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on index innovation and
customer partnership applying the highest industry standards and
embracing the IOSCO Principles. FTSE Russell is wholly owned by
London Stock Exchange Group.
For more information, visit
www.ftserussell.com.
About OptimizeRxOptimizeRx Corporation (NASDAQ:
OPRX) is a digital health company that facilitates communication at
point-of-care among all stakeholders in healthcare. Primarily
focused on life science and payer clients, its suite of digital and
mobile SaaS-based solutions enables affordability, patient
adherence and care management. OptimizeRx’s network reaches more
than 60% of U.S. ambulatory providers, delivering therapeutic
support on specialty medications and patient financial assistance
directly within a provider’s workflow through leading electronic
health platforms. OptimizeRx’s fully integrated platform supports
the real-time exchange of information, improving provider knowledge
and patient engagement, and ultimately leading to healthier
outcomes.
For more information, follow the company on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
StatementsThis press release contains forward-looking
statements within the definition of Section 27A of the Securities
Act of 1933, as amended, and such as in section 21E of the
Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material
risks.
OptimizeRx Contact Doug
Baker, CFOTel (248) 651-6568 (x807)dbaker@optimizerx.com
Media Relations Contact Maira Alejandra,
Media Relations ManagerTel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024